Pre-earnings brief
Reports
Wed, Nov 4, 2026
Est. EPS
—
Est. revenue
—
Implied move
±11.6%
EPS beat rate
88%
Edwards Lifesciences Corporation (EW) specializes in heart valve and hemodynamic monitoring technologies, playing a crucial role in the healthcare sector. As a leader in heart valve replacement and repair, the company is positioned to benefit from the growing demand for innovative medical devices and treatments for cardiovascular diseases.
Last quarter
In Q2 2026, Edwards Lifesciences reported an EPS of $0.78, exceeding expectations by 6.41%. However, the stock experienced a slight decline of 0.65% the following day.
Management promises and guidance
EPS beat streak
2Q
EPS beat rate
88%
Avg EPS surprise
+88.52%
Avg 1-day reaction
-0.48%
Overall, analysts expect Edwards Lifesciences to continue its trend of beating earnings estimates, given its strong track record. However, uncertainty remains regarding revenue growth and market conditions.
Bull case
If the company can demonstrate strong revenue growth and maintain its profitability, it could see significant stock appreciation, especially given its history of EPS beats.
Bear case
Conversely, if the company fails to meet revenue expectations or faces increased competition, it may struggle to maintain its stock price, especially given recent market volatility.
The print will turn on these.
Q1
What will be the reported revenue growth rate for the quarter?
Revenue growth is critical for assessing the company's ability to expand and compete in the healthcare market, especially in light of recent industry trends.
Q2
Will management provide any updates on new product launches or innovations?
Updates on product developments can significantly impact investor sentiment and expectations for future growth.
—
Est. EPS
$-0.50
Est. Rev
$257M
Impl. Move
±7.5%
Why consensus could be wrong
The Street may be underestimating the impact of recent product innovations on revenue growth, which could lead to stronger-than-expected results.
Supporting evidence
The company has a strong track record of beating EPS estimates, with an 88% success rate in the last eight quarters.
Options pricing suggests a significant move, indicating that investors are anticipating volatility that may not be reflected in consensus estimates.
Key risk
If revenue growth exceeds 10%, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance hinges on the company's ability to maintain growth in a competitive landscape and deliver on innovation promises.
Bull confirmed if
Demonstrating revenue growth of 10% or more compared to the previous quarter would confirm the bull case.
Bear confirmed if
If revenue growth falls below 5%, it would support the bear case.
What the market is pricing for the move.
Implied Move
±8.16%
Historical Avg
±0.8%
The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.
Options are pricing ±11.6% while EW has averaged ±0.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
24.3%
Smart-money positioning from the most recent 13F filings.
Institutional
95.61%
of float
Insider
0.19%
of float
Holders
1,917
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
58,789,433 sh · $5.0B
10.21%
11.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Edwards beats expectations and raises guidance, history suggests the stock could see a positive reaction, potentially around a 0.8% increase.
In line / cautious
If results are in line with expectations but management is cautious, the stock may experience muted movement as investors assess future prospects.
Miss
If the company misses earnings expectations, history suggests a potential decline of around 0.33%, reflecting investor disappointment.
The lines on the call that would change the story.
Vanguard Capital Management LLC
37,615,952 sh · $3.2B
6.53%
-0.3%
Vanguard Portfolio Management LLC
26,411,402 sh · $2.3B
4.59%
0.0%
State Street Corporation
26,321,940 sh · $2.3B
4.57%
0.1%
JPMORGAN CHASE & CO
22,783,175 sh · $2.0B
3.96%
4.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.